Dr. David Haase, a functional medicine doctor and a leader in the field of genetics and genomics, covers mitomics in this very interesting interview on the upcoming Interpreting Your Genetics Summit which runs August 21-28, 2017.
Mitomics is the genetics of the mitochondria themselves. The mitochondria have their own set of genes. And that’s often given a lot of importance because we get our mitochondria from our mothers and therefore we inherit this genome from the mother and we get our mother’s energy per se.
But when you step back a little bit, you recognize that the genetics of the mitochondria are not just nuclear. It’s not just thirty-seven genes that hang out in the mitochondria, but rather, there is over a thousand genes that are in the nucleus that control the proteins or make proteins and influence the mitochondria at great levels. I’ve used a company called Courtagen who do whole mitome analysis. And in individuals with chronic fatigue syndrome or bizarre multi-system dysfunction, this is instrumental in giving a new plan of action to address.
He shares the story of a patient who had had chronic pain, fatigue and irritable bowel syndrome (a mitochondrial symptom)
She had tachycardia, palpitations, some dizziness. And so we actually did a whole mitome analysis on her and we found that she had a uniqueness in something called the TRAP1 related disease. I think it’s clever because the acronym is T1RED.
And this TRAP actually codes for a protein, which is a chaperone to the mitochondria and it’s involved in antioxidant defenses. And what’s been shown is that individuals with this TRAP1 related disease will be queasy, they’ll have pain and they’ll be fatigued and highly aggressive.
But when we found that she had this heterozygote for this particular abnormality – and it was associated with her having a lot of oxidative stress and elevation of hydroxyguanidine, which is a marker of genetic damage and oxidative damage, and elevations in her CK [creatine kinase], which was a marker of muscle injury. We went into this very intense antioxidant program with a lot of food-based antioxidants: sulforaphane, curcumin, resveratrol, CoQ10 and alpha-lipoic acid.
We went after this as aggressively as I think I’ve ever gone after this in a single patient with doses that are in excess of what I would typically use. And she had a remarkable recovery.
I share this snippet because with the tachycardia (an abnormally fast resting heart rate of at least 100 beats per minute) and palpitations, you may think it’s anxiety with a root cause such as low GABA or low serotonin or high cortisol or even Hashimoto’s thyroiditis, when in fact these symptoms are caused by mitochondrial TRAP-1 related disease.
Here are some other reasons to attend:
- once you register you’ll have immediate access to these interviews: Epigenetic Mastery for Everyone from Andrea Nakayama, CNC, CNE; The Current State of Genetics from Jeffrey Bland, PhD; and Your Genetics and Autoimmune Diseases with Dr. Tom O’Bryan, DC, CCN.
- my digital ebook is available to you if you choose to purchase the series: Anxiety, Benzodiazepines and Your Genetics
- as part of the lead up to the event, summit host, James Maskell will even be doing three of his own genetic tests and getting them interpreted by speakers from the summit
James Maskell has gathered world-renowned leaders from genetics, genomics and functional medicine and this promises to be a cutting-edge online event. These pioneering experts are on the front lines interpreting genetic data!
Hope to “see you” on the summit.
UPDATE August 11: I just went to the site and see this message today “Courtagen has closed its diagnostic laboratory and will no longer be accepting samples.”
They have a link to this press release of July 18 so it’s a brand new change: “Courtagen Life Sciences Inc. announced today that the company will be shifting the core focus of its business to medicinal cannabis genetics and testing. As the company reorients its business to respond to the growing opportunities in the medicinal cannabis industry, the company has made the decision to wind down its diagnostic neurology testing division.”